Cogent Biosciences Inc COGT

Healthcare Biotechnology

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company also develops CGT4859, a reversible and selective fibroblast growth factor receptor 2 inhibitor in Phase 1 trial for patients with documented FGFR mutations, including advanced cholangiocarcinoma. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. Cogent Biosciences, Inc. is headquartered in Waltham, Massachusetts.

NDAQ:COGT - Post by User

Cogent Biosciences Inc

<< Previous

Bullboard Posts

Next >>

(4)
•••

Post by AviseAnalyticson Nov 15, 2021 7:27am

170 Views

Post# 34126121

COGENT BIOSCIENCES: MASSIVE UPSIDE POTENTIAL!

COGENT BIOSCIENCES: MASSIVE UPSIDE POTENTIAL!

https://www.aviseanalytics.com/cogent-biosciences-massive-upside-potential/

Cogent Biosciences (COGT) is a clinical-stage biotechnology company targeting underlying causes of genetic dysfunction that cause diseases such as cancers, autoimmune disorders and rare diseases.

In October 2021, H.C Wainwright initiated coverage for the stock with a “Buy” rating and a price target of $25, which was later revised to $31, showing a massive upside potential.

We take a look at the Company in our coverage today.

https://www.aviseanalytics.com/cogent-biosciences-massive-upside-potential/

<< Previous

Bullboard Posts

Next >>

Five key facts you need to know about the Sedna Copper Project